Experienced in Autosomal Recessive Hypotrichosis

Dr. Matthew J. Zirwas

Dermatology
Dermatologists Of Southwestern Ohio, LLC
5300 Far Hills Ave, 
Dayton, OH 
Accepting New Patients
Experienced in Autosomal Recessive Hypotrichosis
Dermatologists Of Southwestern Ohio, LLC
5300 Far Hills Ave, 
Dayton, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Matthew Zirwas is a Dermatologist in Dayton, Ohio. Dr. Zirwas is rated as an Experienced provider by MediFind in the treatment of Autosomal Recessive Hypotrichosis. His top areas of expertise are Atopic Dermatitis, Contact Dermatitis, Plaque Psoriasis, and Psoriasis. Dr. Zirwas is currently accepting new patients.

His clinical research consists of co-authoring 136 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles and participated in 2 clinical trials in the study of Autosomal Recessive Hypotrichosis.

Specialties
Dermatology
Licenses
Dermatology in OH
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

DERMATOLOGISTS OF SOUTHWESTERN OHIO, LLC
5300 Far Hills Ave, Dayton, OH 45429
Other Locations
DERMATOLOGISTS OF SOUTHWESTERN OHIO, LLC
2359 E Main St, Bexley, OH 43209

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects with Moderate to Severe Chronic Allergic Contact Dermatitis
A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects with Moderate to Severe Chronic Allergic Contact Dermatitis
Enrollment Status: Completed
Publish Date: November 14, 2024
Intervention Type: Drug
Study Drug: EB01 Cream
Study Phase: Phase 2
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
Enrollment Status: Completed
Publish Date: May 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 9 Less Clinical Trials

136 Total Publications

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study.
Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: June 30, 2025
Similar Doctors
Advanced in Autosomal Recessive Hypotrichosis
Dr. Michael A. Morgan
Dermatology
Advanced in Autosomal Recessive Hypotrichosis
Dr. Michael A. Morgan
Dermatology

Christ Hospital Medical Specialists LLC

2123 Auburn Ave, 
Cincinnati, OH 
 (42.2 miles away)
513-381-6161
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Morgan is a Dermatologist in Cincinnati, Ohio. Dr. Morgan is rated as a Distinguished provider by MediFind in the treatment of Autosomal Recessive Hypotrichosis. His top areas of expertise are Actinic Keratosis, Rosacea, Plaque Psoriasis, and Warts. Dr. Morgan is currently accepting new patients.

Advanced in Autosomal Recessive Hypotrichosis
Dr. Debra S. Anderson
Dermatology
Advanced in Autosomal Recessive Hypotrichosis
Dr. Debra S. Anderson
Dermatology

Christ Hospital Medical Specialists LLC

2123 Auburn Ave, 
Cincinnati, OH 
 (42.2 miles away)
513-381-6161
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Debra Anderson is a Dermatologist in Cincinnati, Ohio. Dr. Anderson is rated as a Distinguished provider by MediFind in the treatment of Autosomal Recessive Hypotrichosis. Her top areas of expertise are Actinic Keratosis, Neurocutaneous Melanosis, Giant Congenital Nevus, and Familial Atypical Multiple Mole Melanoma Syndrome. Dr. Anderson is currently accepting new patients.

Advanced in Autosomal Recessive Hypotrichosis
Dr. Leigh G. Stone
Dermatology
Advanced in Autosomal Recessive Hypotrichosis
Dr. Leigh G. Stone
Dermatology

University Of Cincinnati Physicians Company LLC

222 Piedmont Ave, 
Cincinnati, OH 
 (41.1 miles away)
513-475-7855
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Leigh Stone is a Dermatologist in Cincinnati, Ohio. Dr. Stone is rated as an Advanced provider by MediFind in the treatment of Autosomal Recessive Hypotrichosis. Her top areas of expertise are Melanoma, Actinic Keratosis, Hidradenitis Suppurativa, and Autosomal Recessive Hypotrichosis. Dr. Stone is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zirwas's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile